LMND:NYSELemonade, Inc. Analysis
Data as of 2026-08-25 - not real-time
$53.86
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Lemonade, Inc. trades at $53.86, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. It has lost 23.2% over the past 30 days. Relative strength is 47.5 — neutral — and the MACD signal is bullish. Price has been bracketed by support at $46.16 and resistance at $55.05.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 10.0% above where the shares trade now. Revenue is growing at 79.4% on a -14.2% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 95.6%, a beta of 2.81 and a maximum drawdown of 50.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 3 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 10.0% above where the shares trade now. Revenue is growing at 79.4% on a -14.2% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 95.6%, a beta of 2.81 and a maximum drawdown of 50.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 3 out of 10.
Top Market Events
Lemonade NYSE: LMND today announced that Tim Bixby, Chief Financial Officer, is scheduled to present at the Oppenheimer...27dLemonade: Favorable Reinsurance Shift And Pushing Toward ProfitsLemonade, Inc.Detailed price information for Lemonade Inc LMND-N from The Globe and Mail including charting and trades.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 65.23
- MACD momentum is positive
Medium Term
1–3 yearsCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 65.23
- Analyst targets imply +10.0% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- Negative profit margin of -14.2%
- Analyst targets imply +10.0% versus the current price
- Negative return on equity of -27.0%
Key Metrics & Analysis
Financial Health
Revenue Growth79.40%
Profit Margin-14.19%
P/E Ratio-61.9
ROE-26.96%
ROA-3.27%
Debt/Equity45.33
P/B Ratio8.3
Op. Cash Flow$21.2M
Free Cash Flow$94.4M
Industry P/E17.1
Technical Analysis
TrendBearish
RSI47.5
Support$46.16
Resistance$55.05
MA 20$51.71
MA 50$59.57
MA 200$65.23
MACDBullish
VolumeDecreasing
Fear & Greed Index93.82
Valuation
Fair Value$44.22
Target Price$59.22
Upside/Downside9.96%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.81
Volatility95.60%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.